Dermatology

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

Results from this AoU database study found that Black and Hispanic patients and individuals with physical disabilities were at an increased risk of tinea versicolor.

Participants defined their acne/acne scars as an “intruder and unwanted companion” in the The Letter to my Disease personification exercise.

Though transgender medicine has existed for over 100 years, physicians like Dr. Jackson Turbeville are still looking for opportunities to make healthcare more accessible and affordable for patients seeking treatment for a variety of dermatologic conditions.

Investigators uncovered that the primary driving motivator for indoor tanning had to do with aesthetic concerns, followed by the perception of psychological and physical benefits.

Travis Vandergriff, MD, discusses the unique collaboration with ophthalmologists and urologists in the rare skin condition.

An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.

Despite an increased risk of new-onset psoriasis from TNFi treatment, investigators considered the absolute risk to be “modest”, with 241 patient-years of exposure needed for 1 additional event.

An analysis suggests patients on the biologic fared better with adherence and outcomes than those on competitors including adalimumab.

A dive into the manifestation of the rare skin condition, and the impactful role of dermatologists in diagnosing it early.

New phase 3 data show a microencapsulated form of the topical antiseptic and vitamin D derivative is beneficial and tolerable over 12 weeks.

Savanna Perry, PA-C, discussed the challenge of standing out over influencers and estheticians regarding clinical dermatology insight, and the unique offerings of different platforms.

New data from ECZTRA 6 show improved sleep quality, itch relief and quality of life among teenagers treating atopic dermatitis with the IL-13 inhibitor.

Results from a cross-sectional survey suggest consistent patient preferences for treatment outcomes and means of administration.

Savanna Perry, PA-C, founder of The PA Platform, discusses the strategies and goals that go into building an online audience as a healthcare professional.

New phase 3 extension data show the topical PDE-4 inhibitor provided skin clearance to a significant rate of patients with psoriasis.

Though previous research had demonstrated an increased risk of MetS in patients with psoriasis, this study was first to consider the prevalence of the condition a global scale.

Dr. Brown and Mr. Zavodnick speak on the first and only FDA-approved steroid-free topical medication in its class approved for psoriasis, and the data that bolstered this approval.

Investigators observed that patients with quantifiable levels of brodalumab following 12 weeks of therapy experienced significantly higher PASI reductions that those without.

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

Previous research has suggested that psoriasis could affect both fecundity and fertility, leading to spontaneous abortion and ectopic pregnancy.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

However, comorbidity risk was believed to be substantially different between the two diseases.